Next Article in Journal
Parental Competences and Stress Levels in Mothers of Children with Autism Spectrum Disorders and Children Developing Neurotypically
Previous Article in Journal
Novel Screw Placement Method for Extremely Small Lumbar Pedicles in Scoliosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 4
10.3390/jcm13041117
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Correlation of Plasmatic Amyloid Beta Peptides (Aβ-40, Aβ-42) with Myocardial Injury and Inflammatory Biomarkers in Acute Coronary Syndrome

by
Luis Eduardo Del Moral
1,
Claudia Lerma
2,
Héctor González-Pacheco
3,
Alan Cristhian Chávez-Lázaro
1,
Felipe Massó
1 and
Emma Rodriguez
1,*
1
Translacional Research Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
2
Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
3
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(4), 1117; https://doi.org/10.3390/jcm13041117
Submission received: 15 January 2024 / Revised: 10 February 2024 / Accepted: 13 February 2024 / Published: 16 February 2024
(This article belongs to the Section Cardiology)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background/Objective: Amyloid beta (β) -40 levels increase with age and inflammation states and appear to be associated with clinical manifestations of acute coronary syndrome (ACS). We investigated the correlation of Aβ peptides with myocardial injury and inflammation biomarkers in patients with or without ST elevation myocardial infarction (STEMI, NSTEMI). Methods: This singe-center, cross-sectional, observational, and correlation study included 65 patients with ACS (n = 34 STEMI, 29 males, age = 58 ± 12 years; n = 31 NSTEMI, 22 males, age = 60 ± 12 years) who were enrolled in the coronary care unit within 12 h after symptom onset from February 2022 to May 2023. Aβ peptide levels and biochemical parameters were assessed. Results: NSTEMI patients had a higher prevalence of hypertension (p = 0.039), diabetes (p = 0.043), smoking (p = 0.003), and prior myocardial infarction (p = 0.010) compared to STEMI patients. We observed a higher level of Aβ-42 in NSTEMI (p = 0.001) but no difference in Aβ-40 levels. We also found a correlation between age and NT-proBNP with both Aβ peptides (Aβ-40, Aβ-42) (p = 0.001, p = 0.002 respectively). Conclusions: Our results show that patients with NSTEMI had a higher prevalence of cardiovascular risk factors (hypertension, diabetes, smoking, and prior myocardial infarction). Considering these results, we propose that Aβ-42 can add value to risk stratification in NSTEMI patients.

1. Introduction

Ischemic heart disease is considered the leading cause of mortality worldwide and the main cause of disease burden in developed countries, accounting for nearly 9.4 million deaths in 2021 [1,2]. Ischemic heart disease from a pathophysiological standpoint is a consequence of reduced blood flow from the coronary arteries that supply the energetic necessities of the heart. Reduced blood flow is often caused by coronary atherosclerosis; however, other conditions such as coronary microvascular dysfunction, inflammation, and vasospasm may precipitate myocardial ischemia. Myocardial infarction is the irreversible necrosis of cardiac myocytes due to extended ischemia by the deprivation of oxygen supply and/or inflammatory, metabolic, or toxic insults [3,4,5]. Acute coronary syndromes encompass a spectrum of conditions that include ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina (UA) [6,7]. Coronary thrombus development in vulnerable atherosclerotic plaque is the primary cause of acute coronary syndrome; nevertheless, a considerable number of patients undergoing ACS may be caused by plaque erosion, calcific nodules, coronary spasms, and spontaneous coronary artery dissection [8,9].
Beta amyloid (Aβ) is a peptide with a length of 37–49 amino acids that are produced by the excision of the amyloid precursor peptide (APP). APP can be cleaved by α -secretase (nonamyloidogenic pathway) or β -secretase (amyloidogenic pathway) to produce α or β-C terminal fragments, respectively. The additional breakdown of β-C terminal fragments by γ -secretase can release different cleavage fragments that are further processed into the main isoforms of Aβ, the 40 amino acid Aβ-40 and the 42 amino acid Aβ-42 [10,11]. These primary isoforms are found in vascular lesions and parenchymal lesions in the brain [12]. An experimental study has demonstrated that an early peak of soluble amyloid precursor peptide (sAPP) preceded the liberation of myocardial injury enzymes [13]. There is evidence of the participation of Aβ in thrombosis [14] and clinical manifestations of acute coronary syndrome [15]. Furthermore, Aβ-40 stimulates the activation and adhesion of platelets [16,17,18,19], partially by the PLCγ2-PKC pathway; in addition, platelet aggregation may be further amplified by thromboxane A2 formation and ADP secretion. Aβ-40 can also induce monocytes to release MMP-9, a matrix metalloproteinase capable of increasing the vulnerability of the plaque by disrupting its basement membrane and promoting the infiltration of monocytes/macrophages into atherosclerotic lesions [20,21]. Moreover, Aβ-42 affects coronary endothelial cells and cardiomyocytes, reducing mitochondrial respiration and disruption of fatty acid metabolism in both cell types [22]. However, there are limited studies that addressed the circulating levels of these peptides and conventional biomarkers in ST elevation and non-ST myocardial infarction. In this study, we investigated the correlation of Aβ peptides with myocardial injury and inflammation biomarkers in acute coronary syndrome.

2. Materials and Methods

2.1. Study Population

This single-center, cross-sectional, observational, and correlation study included patients within the first 12 h after the onset of symptoms (chest pain, shoulder pain, or chest discomfort) with acute coronary syndrome who were admitted to the coronary care unit at the Instituto Nacional de Cardiología Ignacio Chávez from Mexico City. Patients’ exclusion criteria were as follows: patients with a history of renal disease, liver failure, autoimmune or autoinflammatory disease, and malignant or hematological disorders. Patients with inadequate blood sample volume to evaluate Aβ peptide (Aβ-42, Aβ-40) concentration, a period of more than 180 min between the collection of blood sample and storage at −80 °C, or those who wish to withdraw consent were eliminated.
The Institutional Research and Ethics committees approved this study (protocol number 21-1275) in compliance with the principles outlined in the Helsinki Declaration. Informed oral and written consent was given by all the subjects participating in this study.

2.2. Sampling Method and Sample Size Determination

A non-probabilistic sampling method (convenience method) was used to select all consecutive patients who fulfilled the selection criteria described above. There are no previous studies on the association between the plasmatic levels of Aβ peptides (Aβ-42 and Aβ-40) and biomarkers of myocardial injury or inflammation in patients with acute coronary syndrome. Therefore, we proposed an expected minimal Pearson correlation coefficient between Aβ peptides (Aβ-42, Aβ-40) and myocardial injury or inflammation biomarkers of 0.3. Assuming a one-tail alfa error of 0.05 and a beta error of 0.2 (i.e., a statistical power of 0.8), we calculated a necessary sample size of 68 subjects using the computer program G*Power version 3.1.9.6 [23].

2.3. Data Collection

The patients’ hospital charts and electronic medical history were reviewed to obtain all clinical data from patients. Clinical characteristics included age, sex, body mass index (kg/m), presence of diabetes, hypertension, dyslipidemia, previous myocardial infarction, smoking status, Killip–Kimball class, Global Registry of Acute Coronary Events (GRACE) score, Thrombolysis In Myocardial Infarction (TIMI) score for ST elevation myocardial infarction (STEMI), TIMI score for unstable angina/non-ST elevation myocardial infarction (UA/NSTEMI) score, Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcome with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) score, and left ventricular ejection fraction (LVEF %). We also gathered time parameters (minutes), such as symptom-to-door, symptom-to-blood sample (time between symptom onset and blood sample collection), door-to-electrocardiogram (ECG), door-to-needle, door-to-balloon, and symptom-to-catheter.
Biochemical values obtained from the electronic medical history included high-sensitivity troponin I (hs-cTnI [pg/mL]), N-terminal pro-B natriuretic peptide (NT-proBNP [pg/mL]), high-sensitivity C-reactive protein (hs-CRP [mg/dL]), total cholesterol (mg/dL), high-density lipoprotein (HDL [mg/dL]), low-density lipoprotein (LDL [mg/dL]), triglycerides (mg/dL), atherogenic index of plasma (AIP), and albumin (g/mL). In addition, we quantified plasmatic levels of Aβ-42 (pg/mL), Aβ-40 (pg/mL), and Aβ-42/40 ratio from a blood sample.

2.4. Assessment of Plasmatic Aβ Peptides (Aβ-42, Aβ-40)

Peripheral blood from subjects was obtained in a 4 mL BD K2EDTA Vacutainer tube. The blood was then centrifuged (1500 rpm, 15 min at 4 °C) and plasma was collected and stored in 200 µL aliquots at −80 °C until Aβ peptide analysis.
After thawing at room temperature, plasmas were used to measure Aβ-42 and Aβ-40 levels with a High-Sensitivity Human Amyloid Aβ-42 ELISA and a High-Sensitivity Human Amyloid Aβ-40 ELISA Kit (both from EMD Millipore Corporation, Billerica, MA, USA) following the manufacturer’s instructions. Absorbance measurements were taken using an imaging reader (BioTek Cytation 3 Cell Imaging Multimode Reader, Agilent, CA, USA) at 450 nm and 590 nm. The measurement range was 16–500 pg/mL for Aβ-42 and Aβ-40. The intra- and inter-assay coefficients of variation of ELISA kits were <10%. No cross-reactivity was observed between Aβ-42 and Aβ-40 antibodies.

2.5. Statistical Methods

Categorical variables are presented as frequencies and percentages. Comparisons were made using the chi-squared test or Fisher’s exact test. The normal distribution of continuous variables was tested using the Kolmogorov–Smirnov method. Continuous variables with a normal distribution are described as mean ± SD and were compared using Student’s t-test. Otherwise, the Mann–Whitney’s U test was used, and variables were described as median (percentile 25–percentile 75). We calculated the correlation between Aβ peptides (Aβ-42, Aβ-40, and Aβ-42/40 ratio) and continuous variables with the Spearman correlation test since none of them had a normal distribution. Receiver operator characteristic (ROC) curve analysis was performed to evaluate the performance of Aβ-42 to distinguish between patients from the STEMI and NSTEMI groups. The shortest orthogonal distance between the ROC curve points and the optimum point (0,1) was calculated to identify the best cut-off value. A multivariate binary regression analysis was applied to assess the independent association of Aβ-42 with the type of myocardial infarction (NSTEMI/STEMI) as the dependent variable when considering Aβ-42, diabetes, hypertension, previous myocardial infarction, smoking status, and the number of SMuRFs as independent variables. The statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 21.0 (IBM Corp., Armonk, NY, USA). A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Overall Patient Characteristics and Demographics

The study sample included 65 patients, with a mean age of 59 ± 13 years. Fifty-one patients (78.5%) were male. Fifty-nine patients (90.8%) had at least one SMuRF (standard modifiable cardiovascular risk factor). The number of patients with risk factors were arterial hypertension, 42 (64.6%), diabetes mellitus, 14 (21.5%), dyslipidemia, 12 (18.5%), smoking, 44 (67.7%), and previous myocardial infarction, 27 (41.5%).
Fourteen patients (21.5%) had a Killip–Kimball of two and above class, forty (61.53%) had an intermediate–high risk GRACE score, forty-two (64.61%) had an intermediate–high risk TIMI score, twenty-nine (44.6%) had a moderate–high risk CRUSADE score, nineteen (30.6%) patients had a mid-range LVEF (left ventricular ejection fraction), and fifteen (24.2%) had reduced a LVEF. The mean symptom-to-door time was 339 ± 191 min, symptom-to-blood sample time was 390 ± 194 min, and symptom-to-catheter time was 2147 ± 2203 min.
Biochemical levels of Aβ-42 were 38.39 (35.39–43.63) pg/mL and Aβ-40 176.20 ± 79.35 pg/mL, the Aβ-42/40 ratio was 0.25 (0.20–0.31), hs-cTnI was 333.0 (67.10–1617.0) pg/mL, NT-proBNP was 342.0 (111.0–975.0), hs-CRP was 4.57 (2.26–9.50) mg/dL, albumin was 4.04 ± 0.48 g/dL, total cholesterol was 165.0 ± 40.7 mg/dL, triglycerides was 157.1 ± 63.3 mg/dL, HDL was 37.6 ± 8.3 mg/dL, LDL was 106.5 ± 38.1 mg/dL, and AIP was 0.23 ± 0.21.

3.2. Aβ Peptide Correlation Analysis

We analyzed the data recovered from our constructed database, and Spearman’s correlation test was applied. Table 1 shows the correlation between the Aβ-42, Aβ-40, and Aβ-42/40 ratio with our study variables. We found a positive correlation between Aβ-42 and Aβ-40 with age, Aβ-42 and Aβ-40 with NT-proBNP, and Aβ-40 with ≥1 SMuRF. Conversely, we found a negative correlation between Aβ-42 and albumin and the Aβ-42/40 ratio with ≥1 SMuRF (ρ = −0.251, p = 0.044). There was no correlation with statistical significance between Aβ-42, Aβ-40, and the Aβ-42/40 ratio and other biochemical variables, such as hs-cTnI, hs-CRP, albumin, total cholesterol, HDL, LDL, triglycerides, and AIP.
Figure 1 provides scatterplots with marginal histograms to represent visually the correlation of Aβ-42, Aβ-40, and Aβ-42/40 with age, NT-proBNP, and albumin. At first glance, we observed a right skewness in the distribution histograms of Aβ-42, Aβ-40, Aβ-42/40 ratio, and NT-proBNP; additionally, in the scatterplots of these variables, some data points were extreme values regarding the main distribution and are considered outliers.
Considering the potential heightened effect of these outliers in the correlation between our study variables, we established cut-off values and repeated the correlation analysis. Outliers were defined by Aβ-42 < 20 pg/mL or >100 pg/mL, Aβ-40 > 400 pg/mL, the Aβ-42/40 ratio < 1.0, and NT-proBNP > 10,000 pg/mL. After this additional analysis, the positive correlation between Aβ-40 with age, Aβ-42, and Aβ-40 with NT-proBNP was maintained; in addition, we observed a negative correlation between the Aβ-42/40 ratio with age. The rest of the correlations were not statistically significant. This analysis is available in the Supplementary Material (Table S1, Figure S1).

3.3. Comparison of Aβ-42 and NT-proBNP with Cardiovascular Risk Factors

Table 2 shows the mean levels of plasmatic Aβ-42 and NT-proBNP between several cardiovascular risk factors, including diabetes, hypertension, dyslipidemia, smoking, prior MI, and two or more SMuRFs. We observed higher levels of Aβ-42 in patients with hypertension compared to those without hypertension, and plasmatic levels of Aβ-42 had a tendency to be higher in patients with diabetes and prior MI when compared to patients without these risk factors. Conversely, Aβ-42 was higher in nonsmokers without dyslipidemia when compared to those who smoked and had dyslipidemia.

3.4. Comparison of Demographic, Clinical, and Biochemical Characteristics between Groups

Table 3 presents the demographic and laboratory baseline characteristics. There were 34 patients in the STEMI group (52%) and 31 patients in the NSTEMI group (47%). We observed a higher prevalence of diabetes, hypertension, smoking, and previous myocardial infarction in the NSTEMI group compared to the STEMI group. When repeating this analysis without outliers, the higher prevalence of hypertension (p = 0.046), previous MI (p = 0.01), and smoking (p = 0.005) in the NSTEMI group when compared to the STEMI group was preserved. These data are available in the Supplementary Material (Table S2).
We observed no difference in hs-cTnI, NT-proBNP, hs-CRP, albumin, total cholesterol, triglycerides, HDL, LDL, or AIP between our study groups (Table 4).
Regarding Aβ peptides, we observed (Figure 2) that circulating levels of Aβ-42 were higher in the NSTEMI group compared to the STEMI group (median level 41.76 [38.99–47.75] vs. 35.96 pg/mL [34.27–39.14]; p = 0.001). There was no evident difference in Aβ-40 and the Aβ-42/Aβ-40 ratio between both groups (Table S3). Interestingly, when repeating this analysis without outliers (Table S4), the plasmatic levels of Aβ-42 were higher in the NSTEMI group compared to the STEMI group (median level 40.26 [37.64–45.13] vs. 35.39 pg/mL [34.27–37.64]; p = 0.001), and no difference between Aβ-42 and the Aβ-42/40 ratio when compared in both groups was found.
The ROC curve analysis in Figure 3 shows that Aβ-42 distinguishes between patients in the STEMI and NSTEMI groups. The cut-off value (Aβ-42 ≥ 38 pg/mL) was estimated as the best to distinguish NSTEMI patients from STEMI patients with the whole sample (sensitivity = 77%, specificity = 74%) and the sample without outliers (sensitivity = 74%, specificity = 80%).
Table 5 shows that having elevated Aβ-42, i.e., Aβ-42 ≥ 38 pg/mL, was independently associated with NSTEMI. The model tested with all patients showed that patients with elevated Aβ-42 had over 12 times higher risk of having NSTEMI, while the risk of having NSTEMI was even higher in the model tested without outliers.

4. Discussion

The traditional classification of acute myocardial infarction (AMI) based on electrocardiogram findings (STEMI or NSTEMI) for the patient’s initial management has led to a more guided approach to the different clinical presentations in the spectrum of acute coronary syndrome [7]. Even though STEMI and NSTEMI have been associated with similar pathophysiologic mechanisms sharing standard modifiable cardiovascular risk factors (SMuRFs) [24], they show different prevalence of these risk factors, including age.
Aβ peptides have been associated with peripheral atherosclerotic manifestations [25], vascular inflammation [12], myocardial dysfunction [26,27], mortality, and adverse cardiovascular outcomes [28,29]. Aβ-40 is related to subclinical cardiovascular disease and has been used for risk stratification in NSTE-ACS [27,28,29,30]. However, there are no studies on the role of Aβ-42 in STEMI and/or NSTEMI. We aimed to investigate the correlation between plasmatic levels of beta-amyloid peptides (Aβ-42, Aβ-40, Aβ-42/40 ratio) with myocardial injury and inflammatory biomarkers in patients with acute coronary syndrome.
Our results showed that NSTEMI patients had a different prevalence of risk factors and Aβ levels. We observed a greater prevalence of hypertension, diabetes, and previous myocardial infarction in NSTEMI when compared to STEMI. These findings were consistent with previous studies performed in the US and Europe [31,32,33]. However, we also found that smoking was more prevalent in NSTEMI patients, opposing the previously reported higher prevalence of smoking in STEMI patients. This difference could be explained because of the inclusion of former smokers in our study as part of the categorization of smoking status. The National Health Interview Survey defined former smokers as adults who had smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of the interview [34]. This additional subcategory was not clear in the aforementioned studies, so further research regarding the impact of former smokers as a risk factor is necessary.
When comparing Aβ peptides (Aβ-40, Aβ-42) in patients with acute coronary syndrome, we found higher levels of Aβ-42 in the NSTEMI group. Aβ-42 levels can distinguish NSTEMI from STEMI patients with sensitivity and specificity above 70%, and the association of elevated Aβ-42 with a higher risk of having NSTEMI was independent of other NSTEMI risk factors (diabetes, hypertension, prior myocardial infarction, and smoking status). The cleavage of APP in endothelial cells [13], macrophages [35], platelets [17], and neurons [36] may be influenced by factors such as aging, ischemia, and inflammation [12]. This enhancement of APP/Aβ processing and inadequate clearance may favor the accumulation of Aβ peptides in the bloodstream, vascular wall [12], and heart tissue [37]. Notably, in previous studies, STEMI patients had a higher mortality rate compared to NSTEMI, but this tendency changes at one- or two-year follow-up when mortality rates become similar between both groups [24]. This may be due to the greater prevalence of cardiovascular risk factors in NSTEMI and could be correlated with enhancing the APP/Aβ processing and residual inflammation over time. To our knowledge, there is no evidence of what could modulate the final processing of APP to generate pathologic cleavage products and subsequently an inclination towards a specific length of Aβ (Aβ-40 or Aβ-42) in each of the different cell types. Platelets have great importance in releasing circulating Aβ peptides [17] along with different pathways of activation in STEMI and NSTEMI, favoring thromboxane receptor and PAR1 pathways, respectively [38]. A recent report demonstrated that human platelets release higher levels of Aβ-42 from α granules in response to the combination of hypoxia and inflammation [39]. In myocardial infarction, platelet activation precedes coronary thrombosis. Therefore, further studies exploring the production or storage of Aβ-42 in these phenotypically different platelets may add value to the usage of Aβ peptides in risk stratification.
We also found a correlation between age and NT-proBNP with both Aβ peptides (Aβ-40, Aβ-42), but albumin only correlates with Aβ-42. Aβ peptide production and clearance can be affected by age-related mechanisms. Neprilysin (NEP) is a metallo-endopeptidase that degrades several bioactive peptides, including Aβ peptides [40], and there is evidence that supports the hypothesis that aging can reduce NEP activity, thereby leading to Aβ accumulation [11]. Furthermore, neuronal aging can increase APP endocytosis, consequently enhancing Aβ production [41]. A study reported that plasmatic levels of Aβ-42 in cognitively and neurologically normal individuals increase with age. However, these levels stabilize after age 65 [42]. With the additional correlation analysis, by excluding potential outliers, only the correlation between Aβ-40 and age was conserved.
The use of circulating natriuretic peptides (NPs), including BNP and NT-proBNP, as clinical biomarkers revolutionized the early recognition of patients with heart failure and ruled out other causes of dyspnea [43], as well as risk stratification after acute myocardial infarction [44]. NPs are secreted by cardiomyocytes through different pathways and are mainly stimulated by myocardial stretching, neurohormones (endothelin 1 and angiotensin II), and circulating cytokines (IL-1β or TNF), which involve Goα, Gqα, or p38 activation [40]. The novel finding of this study is the association of Aβ-42 with NT-proBNP in patients with ongoing acute coronary syndrome. Focusing research on Aβ-42 in acute coronary syndrome in further studies could help explore the underlying participation of this peptide in cardiovascular disease. A study found that plasma Aβ-40 was associated with NT-proBNP, suggesting that Aβ-40 could be involved in early subclinical rise in filling pressure in the general population without overt coronary cardiovascular disease [27]. Moreover, circulating Aβ-40 is a predictor of mortality and can improve risk stratification of patients with NST-ACS over GRACE score [30].
Our results show a negative correlation between Aβ-42 and albumin. Serum albumin has an important role in balancing Aβ peptides between brain and blood plasma due to its capability of binding. A study found that low serum albumin may increase amyloid accumulation in patients with Alzheimer’s Disease [45]. Although, the regulation of Aβ peptides by albumin in cardiovascular disease has not yet been investigated.
On the other hand, we did not find a correlation between Aβ peptides (Aβ-40, Aβ-42) and high-sensitivity troponin I (hs-cTnI). Cardiac troponin I can be detected in serum early after the onset of acute myocardial infarction, and usually peak levels are reached after 12–48 h [46]. Therefore, the timing of the blood sample could have an influence on this association. A study explored the changes in cardiac troponins I and T beyond the initial hours of symptom onset. They found a peak concentration of 6–12 h for cTnI and 12–18 h for cTnT from initial sampling. However, the time between symptom onset and initial sampling is not clear [47].
Finally, there was no correlation between Aβ-42 and high-sensitivity C-reactive protein (hs-CRP) in our population. There is limited information regarding this with ongoing acute coronary syndrome. However, a previous study reported no association between higher levels of CRP and Aβ-42 in cerebral small vessel disease [48].
Our study has some limitations. Firstly, we estimated a population size sample of 68 subjects, which is relatively small and will need to be applied to a larger cohort. Secondly, our study groups were predominantly male and older age adults. Therefore, our findings may need further validation and should not be generalized in female subjects and younger populations. Thirdly, due to the cross-sectional nature of our study, we only assessed Aβ peptide, cardiac injury, and inflammatory biomarkers at the admission of patients who arrived in the first 12 h of symptom onset, although serial determinations of these biomarkers were not part of our objective, further studies regarding the kinetics of these biomarkers are needed. Nevertheless, our results were the first to explore plasmatic levels Aβ-42 with conventional biomarkers in acute coronary syndrome. Additional longitudinal studies are required to determine whether the association of NT-proBNP and both Aβ peptides (Aβ-40, Aβ-42), together with additional echocardiographic measurements, may provide insight into heart failure after myocardial infarction.

5. Conclusions

The present study demonstrates the correlation between Aβ-42 and NT-proBNP in patients with ST elevation and non-ST elevation myocardial infarction. The plasmatic levels of Aβ-42 are higher in NSTEMI when compared to STEMI. Considering the toxic properties of Aβ-42 in coronary endothelial cells and cardiomyocytes, this peptide may be useful in risk stratification scores in patients with NSTEMI. Further longitudinal studies may clarify the role of Aβ-42 in high-risk patients with ongoing acute coronary syndrome.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm13041117/s1, Figure S1. Correlation analysis without outliers; Table S1: Correlation between our study variables and Aβ peptides (Aβ-42, Aβ-40), Aβ-42/40 ratio in 57 patients with acute coronary syndrome; Table S2: Demographic characteristics of 57 patients admitted to the coronary care unit grouped by ST elevation or non-ST elevation myocardial infarction; Table S3. Biochemical values from 65 patients admitted to the coronary care unit; Table S4. Biochemical values from 57 patients admitted to the coronary care unit.

Author Contributions

Conceptualization, E.R. and C.L.; methodology, E.R. and C.L.; software, C.L. and L.E.D.M.; validation, E.R., C.L. and H.G.-P.; formal analysis, C.L. and L.E.D.M.; investigation, E.R., A.C.C.-L. and L.E.D.M.; resources, F.M., H.G.-P. and E.R.; data curation, C.L. and L.E.D.M.; writing—original draft preparation, E.R. and L.E.D.M.; writing—review and editing, L.E.D.M., E.R. and C.L.; visualization, E.R., C.L. and L.E.D.M.; supervision, E.R. and F.M.; project administration, E.R.; funding acquisition, E.R. and F.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Instituto Nacional de Cardiología Ignacio Chávez (protocol number 21-1275). The APC was funded by the Instituto Nacional de Cardiología Ignacio Chávez.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki, and it was approved by the Institutional Review Board of the Instituto Nacional de Cardiología Ignacio Chávez (protocol code 21-1275, 25 November 2021).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available upon request to the corresponding author, provided pertinent legal requirements are met.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Vaduganathan, M.; Mensah, G.A.; Turco, J.V.; Fuster, V.; Roth, G.A. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J. Am. Coll. Cardiol. 2022, 80, 2361–2371. [Google Scholar] [CrossRef] [PubMed]
  2. Lopez, A.D.; Mathers, C.D.; Ezzati, M.; Jamison, D.T.; Murray, C.J.L. Global and Regional Burden of Disease and Risk Factors, 2001: Systematic Analysis of Population Health Data. Lancet 2006, 367, 1747–1757. [Google Scholar] [CrossRef] [PubMed]
  3. Heusch, G. Myocardial Ischemia/Reperfusion: Translational Pathophysiology of Ischemic Heart Disease. Med 2024, 5, 10–31. [Google Scholar] [CrossRef] [PubMed]
  4. Severino, P.; D’amato, A.; Pucci, M.; Infusino, F.; Adamo, F.; Birtolo, L.I.; Netti, L.; Montefusco, G.; Chimenti, C.; Lavalle, C.; et al. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int. J. Mol. Sci. 2020, 21, 8118. [Google Scholar] [CrossRef] [PubMed]
  5. Anderson, H.V.; Masri, S.C.; Abdallah, M.S.; Chang, A.M.; Cohen, M.G.; Elgendy, I.Y.; Gulati, M.; Lapoint, K.; Madan, N.; Moussa, I.D.; et al. 2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards. Circ. Cardiovasc. Qual. Outcomes 2022, 15, e000112. [Google Scholar] [CrossRef]
  6. Bhatt, D.L.; Lopes, R.D.; Harrington, R.A. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA 2022, 327, 662–675. [Google Scholar] [CrossRef] [PubMed]
  7. Byrne, R.A.; Rossello, X.; Coughlan, J.J.; Barbato, E.; Berry, C.; Chieffo, A.; Claeys, M.J.; Dan, G.A.; Dweck, M.R.; Galbraith, M.; et al. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. Eur. Heart J. 2023, 44, 3720–3826. [Google Scholar] [CrossRef]
  8. Libby, P.; Pasterkamp, G.; Crea, F.; Jang, I.K. Reassessing the Mechanisms of Acute Coronary Syndromes: The “Vulnerable Plaque” and Superficial Erosion. Circ. Res. 2019, 124, 150–160. [Google Scholar] [CrossRef]
  9. Nardin, M.; Verdoia, M.; Laera, N.; Cao, D.; De Luca, G. New Insights into Pathophysiology and New Risk Factors for ACS. J. Clin. Med. 2023, 12, 2883. [Google Scholar] [CrossRef]
  10. Roher, A.E.; Kokjohn, T.A.; Clarke, S.G.; Sierks, M.R.; Maarouf, C.L.; Serrano, G.E.; Sabbagh, M.S.; Beach, T.G. APP/Aβ Structural Diversity and Alzheimer’s Disease Pathogenesis. Neurochem. Int. 2017, 110, 1–13. [Google Scholar] [CrossRef]
  11. Chen, G.F.; Xu, T.H.; Yan, Y.; Zhou, Y.R.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development. Acta Pharmacol. Sin. 2017, 38, 1205–1235. [Google Scholar] [CrossRef] [PubMed]
  12. Stakos, D.A.; Stamatelopoulos, K.; Bampatsias, D.; Sachse, M.; Zormpas, E.; Vlachogiannis, N.I.; Tual-Chalot, S.; Stellos, K. The Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease: JACC Focus Seminar. J. Am. Coll. Cardiol. 2020, 75, 952–967. [Google Scholar] [CrossRef] [PubMed]
  13. Kitazume, S.; Yoshihisa, A.; Yamaki, T.; Oikawa, M.; Tachida, Y.; Ogawa, K.; Imamaki, R.; Takeishi, Y.; Yamamoto, N.; Taniguchi, N. Soluble Amyloid Precursor Protein 770 Is a Novel Biomarker Candidate for Acute Coronary Syndrome. Proteom. Clin. Appl. 2013, 7, 657–663. [Google Scholar] [CrossRef] [PubMed]
  14. Zamolodchikov, D.; Renné, T.; Strickland, S. The Alzheimer’s Disease Peptide β-Amyloid Promotes Thrombin Generation through Activation of Coagulation Factor XII. J. Thromb. Haemost. 2016, 14, 995–1007. [Google Scholar] [CrossRef] [PubMed]
  15. Stamatelopoulos, K.; Sibbing, D.; Rallidis, L.S.; Georgiopoulos, G.; Stakos, D.; Braun, S.; Gatsiou, A.; Sopova, K.; Kotakos, C.; Varounis, C.; et al. Amyloid-Beta (1-40) and the Risk of Death from Cardiovascular Causes in Patients with Coronary Heart Disease. J. Am. Coll. Cardiol. 2015, 65, 904–916. [Google Scholar] [CrossRef] [PubMed]
  16. Herczenik, E.; Bouma, B.; Korporaal, S.J.A.; Strangi, R.; Zeng, Q.; Gros, P.; Van Eck, M.; Van Berkel, T.J.C.; Gebbink, M.F.B.G.; Akkerman, J.W.N. Activation of Human Platelets by Misfolded Proteins. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1657–1665. [Google Scholar] [CrossRef] [PubMed]
  17. Shen, M.Y.; Hsiao, G.; Fong, T.H.; Chou, D.S.; Sheu, J.R. Expression of Amyloid Beta Peptide in Human Platelets: Pivotal Role of the Phospholipase Cγ2-Protein Kinase C Pathway in Platelet Activation. Pharmacol. Res. 2008, 57, 151–158. [Google Scholar] [CrossRef] [PubMed]
  18. Gowert, N.S.; Donner, L.; Chatterjee, M.; Eisele, Y.S.; Towhid, S.T.; Münzer, P.; Walker, B.; Ogorek, I.; Borst, O.; Grandoch, M.; et al. Blood Platelets in the Progression of Alzheimer’s Disease. PLoS ONE 2014, 9, e90523. [Google Scholar] [CrossRef]
  19. Canobbio, I.; Catricalà, S.; Di Pasqua, L.G.; Guidetti, G.; Consonni, A.; Manganaro, D.; Torti, M. Immobilized Amyloid Aβ Peptides Support Platelet Adhesion and Activation. FEBS Lett. 2013, 587, 2606–2611. [Google Scholar] [CrossRef]
  20. Li, T.; Li, X.; Feng, Y.; Dong, G.; Wang, Y.; Yang, J. The Role of Matrix Metalloproteinase-9 in Atherosclerotic Plaque Instability. Mediat. Inflamm. 2020, 2020, 3872367. [Google Scholar] [CrossRef]
  21. Chong, Y.H.; Sung, J.H.; Shin, S.A.; Chung, J.H.; Suh, Y.H. Effects of the β-Amyloid and Carboxyl-Terminal Fragment of Alzheimer’s Amyloid Precursor Protein on the Production of the Tumor Necrosis Factor-α and Matrix Metalloproteinase-9 by Human Monocytic THP-1. J. Biol. Chem. 2001, 276, 23511–23517. [Google Scholar] [CrossRef]
  22. Jang, S.; Chapa-Dubocq, X.R.; Parodi-Rullán, R.M.; Fossati, S.; Javadov, S. Beta-Amyloid Instigates Dysfunction of Mitochondria in Cardiac Cells. Cells 2022, 11, 373. [Google Scholar] [CrossRef]
  23. Faul, F.; Erdfelder, E.; Lang, A.-G.; Buchner, A. G * Power 3: A Flexible Statistical Power Analysis Program for the Social, Behavioral, and Biomedical Sciences. Behav. Res. Methods 2007, 39, 175–191. [Google Scholar] [CrossRef]
  24. Mitsis, A.; Gragnano, F. Myocardial Infarction with and without ST-Segment Elevation: A Contemporary Reappraisal of Similarities and Differences. Curr. Cardiol. Rev. 2020, 17, e230421189013. [Google Scholar] [CrossRef]
  25. Kokjohn, T.A.; Van Vickle, G.D.; Maarouf, C.L.; Kalback, W.M.; Hunter, J.M.; Daugs, I.D.; Luehrs, D.C.; Lopez, J.; Brune, D.; Sue, L.I.; et al. Chemical Characterization of Pro-Inflammatory Amyloid-Beta Peptides in Human Atherosclerotic Lesions and Platelets. Biochim Biophys. Acta Mol. Basis Dis. 2011, 1812, 1508–1514. [Google Scholar] [CrossRef]
  26. Troncone, L.; Luciani, M.; Coggins, M.; Wilker, E.H.; Ho, C.-Y.; Codispoti, K.E.; Frosch, M.P.; Kayed, R.; del Monte, F. Aβ Amyloid Pathology Affects the Hearts of Patients with Alzheimer’s Disease: Mind the Heart. J. Am. Coll. Cardiol. 2016, 68, 2395–2407. [Google Scholar] [CrossRef] [PubMed]
  27. Stamatelopoulos, K.; Pol, C.J.; Ayers, C.; Georgiopoulos, G.; Gatsiou, A.; Brilakis, E.S.; Khera, A.; Drosatos, K.; de Lemos, J.A.; Stellos, K. Amyloid-Beta (1-40) Peptide and Subclinical Cardiovascular Disease. J. Am. Coll. Cardiol. 2018, 72, 1060–1061. [Google Scholar] [CrossRef]
  28. Stellos, K.; Sibbing, D.; Stakos, D.; Braun, S.; Georgiopoulos, G.; Gatsiou, A.; Sopova, K.; Kastrati, A.; Stamatelopoulos, K. Association of Plasma Amyloid-Beta (1-40) Levels with Incident Coronary Artery Disease and Cardiovascular Mortality. Eur. Heart J. 2013, 34 (Suppl. 1), 3145. [Google Scholar] [CrossRef]
  29. Bayes-Genis, A.; Barallat, J.; de Antonio, M.; Domingo, M.; Zamora, E.; Vila, J.; Subirana, I.; Gastelurrutia, P.; Pastor, M.C.; Januzzi, J.L.; et al. Bloodstream Amyloid-Beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. Rev. Esp. Cardiol. (Engl. Ed.) 2017, 70, 924–932. [Google Scholar] [CrossRef] [PubMed]
  30. Stamatelopoulos, K.; Mueller-Hennessen, M.; Georgiopoulos, G.; Sachse, M.; Boeddinghaus, J.; Sopova, K.; Gatsiou, A.; Amrhein, C.; Biener, M.; Vafaie, M.; et al. Amyloid-(1-40) and Mortality in Patients with Non–ST-Segment Elevation Acute Coronary Syndrome A Cohort Study. Ann. Intern Med. 2018, 168, 855–865. [Google Scholar] [CrossRef] [PubMed]
  31. Rosengren, A.; Wallentin, L.; Simoons, M.; Gitt, A.K.; Behar, S.; Battler, A.; Hasdai, D. Cardiovascular Risk Factors and Clinical Presentation in Acute Coronary Syndromes. Heart 2005, 91, 1141–1147. [Google Scholar] [CrossRef]
  32. Gandhi, S.; Garratt, K.N.; Li, S.; Wang, T.Y.; Bhatt, D.L.; Davis, L.L.; Zeitouni, M.; Kontos, M.C. Ten-Year Trends in Patient Characteristics, Treatments, and Outcomes in Myocardial Infarction from National Cardiovascular Data Registry Chest Pain-MI Registry. Circ. Cardiovasc. Qual. Outcomes 2022, 15, E008112. [Google Scholar] [CrossRef]
  33. Mandelzweig, L. The Second Euro Heart Survey on Acute Coronary Syndromes: Characteristics, Treatment, and Outcome of Patients with ACS in Europe and the Mediterranean Basin in 2004. Eur. Heart J. 2006, 27, 2285–2293. [Google Scholar] [CrossRef]
  34. NHIS-Adult Tobacco Use-Glossary. Available online: https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm (accessed on 14 December 2023).
  35. De Meyer, G.R.Y.; De Cleen, D.M.M.; Cooper, S.; Knaapen, M.W.M.; Jans, D.M.; Martinet, W.; Herman, A.G.; Bult, H.; Kockx, M.M. Platelet Phagocytosis and Processing of β-Amyloid Precursor Protein as a Mech anism of Macrophage Activation in Atherosclerosis. Circ. Res. 2002, 90, 1197–1204. [Google Scholar] [CrossRef] [PubMed]
  36. Wang, H.; Kulas, J.A.; Wang, C.; Holtzman, D.M.; Ferris, H.A.; Hansen, S.B. Regulation of Beta-Amyloid Production in Neurons by Astrocyte-Derived Cholesterol. Proc. Natl. Acad. Sci. USA 2021, 118, e2102191118. [Google Scholar] [CrossRef] [PubMed]
  37. Zhu, F.; Wolters, F.J.; Yaqub, A.; Leening, M.J.G.; Ghanbari, M.; Boersma, E.; Ikram, M.A.; Kavousi, M. Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population. JACC Heart Fail. 2023, 11, 93–102. [Google Scholar] [CrossRef] [PubMed]
  38. Schmidt, R.A.; Morrell, C.N.; Ling, F.S.; Simlote, P.; Fernandez, G.; Rich, D.Q.; Adler, D.; Gervase, J.; Cameron, S.J. The Platelet Phenotype in Patients with ST-Segment Elevation Myocardial Infarction Is Different from Non–ST-Segment Elevation Myocardial Infarction. Transl. Res. 2018, 195, 1–12. [Google Scholar] [CrossRef] [PubMed]
  39. Wolska, N.; Celikag, M.; Failla, A.V.; Tarafdar, A.; Renné, T.; Torti, M.; Canobbio, I.; Pula, G. Human Platelets Release Amyloid Peptides Β1-40 and Β1-42 in Response to Hemostatic, Immune, and Hypoxic Stimuli. Res. Pract. Thromb. Haemost. 2023, 7, 100154. [Google Scholar] [CrossRef] [PubMed]
  40. Bozkurt, B.; Nair, A.P.; Misra, A.; Scott, C.Z.; Mahar, J.H.; Fedson, S. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions. JACC Basic Transl. Sci. 2023, 8, 88–105. [Google Scholar] [CrossRef]
  41. Burrinha, T.; Martinsson, I.; Gomes, R.; Terrasso, A.P.; Gouras, G.K.; Almeida, C.G. Upregulation of APP Endocytosis by Neuronal Aging Drives Amyloid-Dependent Synapse Loss. J. Cell Sci. 2021, 134, jcs255752. [Google Scholar] [CrossRef] [PubMed]
  42. Zecca, C.; Pasculli, G.; Tortelli, R.; Dell’Abate, M.T.; Capozzo, R.; Barulli, M.R.; Barone, R.; Accogli, M.; Arima, S.; Pollice, A.; et al. The Role of Age on Beta-Amyloid1–42 Plasma Levels in Healthy Subjects. Front. Aging Neurosci. 2021, 13, 698571. [Google Scholar] [CrossRef]
  43. Heidenreich, P.A.; Bozkurt, B.; Aguilar, D.; Allen, L.A.; Byun, J.J.; Colvin, M.M.; Deswal, A.; Drazner, M.H.; Dunlay, S.M.; Evers, L.R.; et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022, 145, e895–e1032. [Google Scholar] [CrossRef]
  44. Jering, K.S.; Claggett, B.L.; Pfeffer, M.A.; Granger, C.B.; Køber, L.; Lewis, E.F.; Maggioni, A.P.; Mann, D.L.; McMurray, J.J.V.; Prescott, M.F.; et al. Prognostic Importance of NT-ProBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circ. Heart Fail. 2023, 16, e010259. [Google Scholar] [CrossRef]
  45. Kim, J.W.; Byun, M.S.; Lee, J.H.; Yi, D.; Jeon, S.Y.; Sohn, B.K.; Lee, J.Y.; Shin, S.; Kim, Y.K.; Kang, K.M.; et al. Serum Albumin and Beta-Amyloid Deposition in the Human Brain. Neurology 2020, 95, e815–e826. [Google Scholar] [CrossRef] [PubMed]
  46. Lazar, D.R.; Lazar, F.L.; Homorodean, C.; Cainap, C.; Focsan, M.; Cainap, S.; Olinic, D.M. High-Sensitivity Troponin: A Review on Characteristics, Assessment, and Clinical Implications. Dis. Mark. 2022, 2022, 9713326. [Google Scholar] [CrossRef] [PubMed]
  47. Kleemeier, S.; Abildgaard, A.; Ladefoged, S.A.; Thorsted Sørensen, J.; Stengaard, C.; Adelborg, K. High-Sensitivity Troponin T and I in Patients Suspected of Acute Myocardial Infarction. Scand. J. Clin. Lab. Investig. 2022, 82, 96–103. [Google Scholar] [CrossRef] [PubMed]
  48. Hilal, S.; Ikram, M.A.; Verbeek, M.M.; Franco, O.H.; Stoops, E.; Vanderstichele, H.; Niessen, W.J.; Vernooij, M.W. C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction with Magnetic Resonance Imaging Markers. Stroke 2018, 49, 2692–2698. [Google Scholar] [CrossRef] [PubMed]
Jcm 13 01117 g001
Figure 1. Scatterplot matrix and marginal histograms (with Spearman’s correlation coefficients) showing the relation between Aβ-42 vs. age, NT-proBNP, and albumin (top row); Aβ-40 vs. age, NT-proBNP, and albumin (middle row); Aβ-42/40 ratio vs. age, NT-proBNP, and albumin (bottom row). Spearman’s correlation (Rho) and p value are shown.
Figure 1. Scatterplot matrix and marginal histograms (with Spearman’s correlation coefficients) showing the relation between Aβ-42 vs. age, NT-proBNP, and albumin (top row); Aβ-40 vs. age, NT-proBNP, and albumin (middle row); Aβ-42/40 ratio vs. age, NT-proBNP, and albumin (bottom row). Spearman’s correlation (Rho) and p value are shown.
Jcm 13 01117 g001
Jcm 13 01117 g002
Figure 2. Box plot of plasmatic levels of Aβ-42, Aβ-40, and the Aβ-42/40 ratio evaluated in the STEMI and NSTEMI groups considering all patients (top row) and without outliers (bottom row).
Figure 2. Box plot of plasmatic levels of Aβ-42, Aβ-40, and the Aβ-42/40 ratio evaluated in the STEMI and NSTEMI groups considering all patients (top row) and without outliers (bottom row).
Jcm 13 01117 g002
Jcm 13 01117 g003
Figure 3. ROC curve analysis of plasmatic levels of Aβ-42 to distinguish patients in the NSTEMI group and the STEMI group. The gray arrows indicate the shortest orthogonal distance between the ROC curve points and the optimum value (0,1). AUC = area under the curve; CI = confidence interval.
Figure 3. ROC curve analysis of plasmatic levels of Aβ-42 to distinguish patients in the NSTEMI group and the STEMI group. The gray arrows indicate the shortest orthogonal distance between the ROC curve points and the optimum value (0,1). AUC = area under the curve; CI = confidence interval.
Jcm 13 01117 g003
Table 1. The correlation between our study variables and Aβ peptides (Aβ-42, Aβ-40) and the Aβ-42/40 ratio in patients with acute coronary syndrome. Data were analyzed using Spearman’s correlation test.
Table 1. The correlation between our study variables and Aβ peptides (Aβ-42, Aβ-40) and the Aβ-42/40 ratio in patients with acute coronary syndrome. Data were analyzed using Spearman’s correlation test.
VariableAβ-42 (pg/mL)Aβ-40 (pg/mL)Aβ-42/40 Ratio
Rhop-ValueRhop-ValueRhop-Value
Age (years)0.3030.0140.3890.001−0.2240.073
BMI (kg/m2)−0.0500.694−0.0840.507−0.0310.805
One or more SMuRF0.1670.1840.2980.016−0.2510.044
High-sensitivity troponin I (pg/mL)−0.0210.8690.0630.617−0.1420.260
CRP (mg/dL)0.0730.5840.1740.190−0.1550.247
NT-proBNP0.4170.0010.3740.002−0.1290.305
Albumin (g/dL)−0.2840.048−0.1730.2340.0480.741
Total cholesterol (mg/dL)−0.1530.274−0.0890.526 0.0610.664
HDL (mg/dL)−0.0050.9720.0610.657−0.0430.757
LDL (mg/dL)−0.1470.285−0.0960.4840.0900.515
Triglycerides −0.0740.611−0.0510.726−0.0510.725
AIP−0.0730.617−0.0790.585−0.0240.869
Symptom-to-blood sample †0.0120.923−0.1420.2590.0490.697
† Time between symptom onset and blood sample collection.
Table 2. Aβ-42 and NT-proBNP compared by the presence of cardiovascular risk factors, including diabetes, hypertension, dyslipidemia, smoking, and prior myocardial infarction. Data are shown as median (percentile 25–percentile 75).
Table 2. Aβ-42 and NT-proBNP compared by the presence of cardiovascular risk factors, including diabetes, hypertension, dyslipidemia, smoking, and prior myocardial infarction. Data are shown as median (percentile 25–percentile 75).
VariableAll Subjects
(n = 65)
Aβ-42
(pg/mL)		p-ValueNT-proBNP (pg/mL)p-Value
Diabetes
Yes:
No: 		42.50 (36.51–47.75)
37.64 (35.01–43.63)		0.0753978.0 (226.0–7611.0)
277.0 (110.0–690.0)		0.004
Hypertension
Yes:
No: 		39.70 (36.51–49.62)
36.14 (34.64–39.51)		0.006551.0 (181.0–1862.0)
231.0 (110.0–522.0)		0.056
Dyslipidemia
Yes:
No: 		37.07 (35.58–39.13)
38.76 (35.39–44.38)		0.393415.5 (76.7–1192.5)
342.0 (125.0–974.0)		0.819
Smoking
Yes:
No:		38.39 (35.39–43.25)
38.57 (35.76–48.68)		0.624226.0 (99.0–975.0)
642.5 (257.5–1125.0)		0.060
Prior MI
Yes:
No: 		40.26 (36.14–53.37)
37.45 (35.01–41.76)		0.066516.0 (199.0–1862.0)
257.5 (110.0–766.0)		0.197
SMuRF
≥One:
None:		38.76 (35.76–45.13)
35.01 (33.52–37.64)		0.039315.0 (110.0–978.0)
470.0 (234.0–642.0)		0.910
Table 3. Demographic characteristics of 65 patients admitted to the coronary care unit grouped by ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI). Data are shown as mean ± standard, median (percentile 25–percentile 75), and absolute value (percentage).
Table 3. Demographic characteristics of 65 patients admitted to the coronary care unit grouped by ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI). Data are shown as mean ± standard, median (percentile 25–percentile 75), and absolute value (percentage).
VariableSTEMI
(n = 34)		NSTEMI
(n = 31)		p-Value
Age (years)58 ± 1260 ± 120.503
Sex
 Male
 Female		29 (85.3%)
5 (14.7%)		22 (71.1%)
9 (29.9%)		0.135
Body mass index (kg/m2)
 Overweight
 Obesity
 Overweight/Obesity		28.28 ± 4.15
14 (41.2%)
12 (35.3%)
26 (76.5%)		27.83 ± 3.70
14 (45.2%)
9 (29.0%)
23 (74.0%)		0.652
Diabetes4 (11.8%)10 (32.3%)0.043
Hypertension18 (52.9%)24 (77.4%)0.039
Dyslipidemia6 (17.6%)6 (19.4%)0.859
Previous myocardial infarction9 (26.5%)18 (58.1%)0.010
Smoking status
 Current smoker
 Former smoker
 Nonsmoker		16 (47.1%)
6 (17.6%)
12 (35.3%)		5 (16.1%)
17 (54.8%)
9 (29.1%)		0.003
Number of SMuRFs
 One or more
 None		29 (85.3%)
5 (14.7%)		30 (96.3%)
1 (3.7%)		0.121
Killip–Kimball
 ≥2 Class9 (26.5%)5 (16.1%)0.240
GRACE
 Intermediate–High Risk22 (64.7%)18 (58.1%)0.583
TIMI
 Intermediate–High Risk21 (61.8%)21 (67.7%)0.615
CRUSADE
 Moderate–High Risk14 (41.2%) 15 (48.4%)0.559
LVEF
 Mid-range ejection fraction
 Reduced ejection fraction		9 (27.3%)
11 (33.3%)		6 (20.7%)
8 (27.6%)		0.618
Symptom-to-door time (minutes)392 ± 196280 ± 171 0.018
Symptom-to-blood sample time (minutes)418 ± 198364 ± 1930.221
Door-to-electrocardiogram time (minutes)6 (5–8)5 (5–7)0.143
Door-to-balloon time (minutes)508 (98–2377)
(n = 31)		2030 (1085–3576)
(n = 16)		0.001
Symptom-to-catheter time (minutes)1700 ± 18893070 ± 25620.992
Table 4. Biochemical values from 65 patients admitted to the coronary care unit grouped by ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI). Data are shown as mean ± standard deviation or median (percentile 25–percentile 75).
Table 4. Biochemical values from 65 patients admitted to the coronary care unit grouped by ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI). Data are shown as mean ± standard deviation or median (percentile 25–percentile 75).
Variable STEMI
(n = 34) 		NSTEMI
(n = 31) 		p-Value
Aβ-42 (pg/mL)35.96 (34.27–39.14)41.76 (38.99–47.75)0.001
Aβ-40 (pg/mL)169.38 ± 88.26183.68 ± 68.960.472
Aβ-42/40 ratio0.25 (0.21–0.30)0.24 (0.20–0.38)0.708
High-sensitivity troponin I (pg/mL)368.5 (67.1–4742.0)249 (65.3–1299.0)0.281
NT-proBNP (pg/mL)257.5 (104.0–643.0)516.0 (199.0–643.0)0.097
High-sensitivity CRP (mg/dL)4.98 (2.47–9.50)4.46 (1.63–10.40)0.569
Albumin (g/dL)4.14 ± 0.423.95 ± 0.520.149
Total cholesterol (mg/dL)170.3 ± 43.7157.5 ± 35.70.264
Triglycerides (mg/dL)162.2 ± 65.8149.4 ± 60.30.490
HDL (mg/dL)38.65 ± 8.8136.21 ± 7.650.285
LDL (mg/dL)112.9 ± 41.498.1 ± 32.30.155
AIP0.23 ± 0.230.23 ± 0.200.992
Table 5. Multivariate logistic regression analysis of the association between the type of myocardial infarction (STEMI or NSTEMI) as a dependent variable and Aβ-42, diabetes, hypertension, previous MI, smoking status, and the number of SMuRFs as independent variables. Odds ratio (OR) are shown as absolute values.
Table 5. Multivariate logistic regression analysis of the association between the type of myocardial infarction (STEMI or NSTEMI) as a dependent variable and Aβ-42, diabetes, hypertension, previous MI, smoking status, and the number of SMuRFs as independent variables. Odds ratio (OR) are shown as absolute values.
VariableAll Patients
(n = 65)		Without Outliers
(n = 57)
β CoefficientOR (95% CI)p-Valueβ CoefficientOR (95% CI)p-Value
Aβ-42 ≥ 38 pg/mL2.57913.184 (2.943–59.053)0.0013.67239.313 (4.479–345.063)0.001
Diabetes1.5934.918 (0.820–29.510)0.0811.9967.361 (0.714–75.859)0.093
Hypertension−0.6960.499 (0.090–2.753)0.425−0.7950.451 (0.071–2.856)0.398
Previous myocardial infarction1.2923.639 (0.763–17.351)2.1318.4248.424 (1.087–65.268)0.041
Smoking status *
Former smoker
Nonsmoker 		1.582
−0.916		4.863 (0.915–25.838)
0.400 (0.083–1.940)		0.063
0.256		2.333
−1.004		10.308 (1.210–87.783)
0.366 (0.056–2.427)		0.033
0.298
* Current smoker is the reference category.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Del Moral, L.E.; Lerma, C.; González-Pacheco, H.; Chávez-Lázaro, A.C.; Massó, F.; Rodriguez, E. Correlation of Plasmatic Amyloid Beta Peptides (Aβ-40, Aβ-42) with Myocardial Injury and Inflammatory Biomarkers in Acute Coronary Syndrome. J. Clin. Med. 2024, 13, 1117. https://doi.org/10.3390/jcm13041117

AMA Style

Del Moral LE, Lerma C, González-Pacheco H, Chávez-Lázaro AC, Massó F, Rodriguez E. Correlation of Plasmatic Amyloid Beta Peptides (Aβ-40, Aβ-42) with Myocardial Injury and Inflammatory Biomarkers in Acute Coronary Syndrome. Journal of Clinical Medicine. 2024; 13(4):1117. https://doi.org/10.3390/jcm13041117

Chicago/Turabian Style

Del Moral, Luis Eduardo, Claudia Lerma, Héctor González-Pacheco, Alan Cristhian Chávez-Lázaro, Felipe Massó, and Emma Rodriguez. 2024. "Correlation of Plasmatic Amyloid Beta Peptides (Aβ-40, Aβ-42) with Myocardial Injury and Inflammatory Biomarkers in Acute Coronary Syndrome" Journal of Clinical Medicine 13, no. 4: 1117. https://doi.org/10.3390/jcm13041117

APA Style

Del Moral, L. E., Lerma, C., González-Pacheco, H., Chávez-Lázaro, A. C., Massó, F., & Rodriguez, E. (2024). Correlation of Plasmatic Amyloid Beta Peptides (Aβ-40, Aβ-42) with Myocardial Injury and Inflammatory Biomarkers in Acute Coronary Syndrome. Journal of Clinical Medicine, 13(4), 1117. https://doi.org/10.3390/jcm13041117

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop